Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Colin Ray is active.

Publication


Featured researches published by Colin Ray.


ChemMedChem | 2012

Sulfonimidamides as Sulfonamides Bioisosteres: Rational Evaluation through Synthetic, in Vitro, and in Vivo Studies with γ-Secretase Inhibitors

Fernando Sehgelmeble; Juliette Janson; Colin Ray; Susanne Rosqvist; Susanne Gustavsson; Linda I. Nilsson; Alexander Minidis; Jörg Holenz; Didier Rotticci; Johan Lundkvist; Per I. Arvidsson

The proof of the pudding: A proof-of-concept study using γ-secretase inhibitors as a model has shown that sulfonimidamides act as bioisosteres for sulfonamides. Detailed in vitro and in vivo profiling reveal that the sulfonimidamide motif imparts desirable properties such as decreased lipophilicity and plasma protein binding, accompanied by increased solubility. Our data support a wider use of this unique functional group in the design of new pharmacologically active agents.


Journal of Medicinal Chemistry | 2013

Substituted 7-Amino-5-thio-thiazolo[4,5-d]pyrimidines as Potent and Selective Antagonists of the Fractalkine Receptor (CX3CR1)

Sofia Karlström; Gunnar Nordvall; Daniel Sohn; Andreas Hettman; Kristofer Åhlin; Annika Kers; Martina Claesson; Can Slivo; Yvonne Lo-Alfredsson; Carl Petersson; Galina Bessidskaia; Per H. Svensson; Tobias Rein; Eva Jerning; Åsa Malmberg; Charlotte Ahlgen; Colin Ray; Lauri Vares; Vladimir Ivanov; Rolf Johansson

We have developed two parallel series, A and B, of CX3CR1 antagonists for the treatment of multiple sclerosis. By modifying the substituents on the 7-amino-5-thio-thiazolo[4,5-d]pyrimidine core structure, we were able to achieve compounds with high selectivity for CX3CR1 over the closely related CXCR2 receptor. The structure-activity relationships showed that a leucinol moiety attached to the core-structure in the 7-position together with α-methyl branched benzyl derivatives in the 5-position displayed promising affinity, and selectivity as well as physicochemical properties, as exemplified by compounds 18a and 24h. We show the preparation of the first potent and selective orally available CX3CR1 antagonists.


Archive | 2006

Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders

Per I. Arvidsson; Erwan Arzel; Jeremy N. Burrows; Martina Claesson; Colin Ray; Tobias Rein; Didier Rotticci; Peter Söderman


Archive | 2006

Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794

Gunnar Nordvall; Colin Ray; Tobias Rein; Daniel Sohn


Archive | 2006

Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives

Gunnar Nordvall; Colin Ray; Tobias Rein; Daniel Sohn


Archive | 2006

Novel 5-substituted 7-amino-ý1,3¨thiazoloý4,5-d¨pyrimidine derivatives

Gunnar Nordvall; Colin Ray; Tobias Rein; Daniel Sohn


Archive | 2010

5,7-disubstituted thiazolo[4,5-D]pyrimidines as chemokine inhibitors

Gunnar Nordvall; Colin Ray; Tobias Rein; Daniel Sohn


Archive | 2006

Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793

Gunnar Nordvall; Colin Ray; Tobias Rein; Daniel Sohn


Archive | 2011

5,7-disubstituted thiazolo[4,5-D]pyrimidines for the selective inhibition of chemokine receptors

Gunnar Nordvall; Colin Ray; Tobias Rein; Daniel Sohn


Archive | 2007

DERIVADOS SUSTITUIDOS DE 3H-IMIDAZOL-(4,5 B (BETA))PIRIDINA-2-IL BENZOATOS Y BENZAMIDAS, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y APLICACIONES

Arvidsson Per I; Burrows Jeremy; Claesson Martina; Soderman Peter; Arzel Erwan; Rotticci Didier; Tobias Rein; Colin Ray

Collaboration


Dive into the Colin Ray's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge